Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy-Reference-Cited by-同舟云学术

Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy

Published:2018-01-22 Issue:1 Volume:13 Page:e0190854
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Sathe Anuja,Chalaud Géraldine,Oppolzer Immanuel,Wong Kit Yeng,von Busch Margarita,Schmid Sebastian C.,Tong Zhichao,Retz Margitta,Gschwend Juergen E.,Schulz Wolfgang A.,Nawroth Roman^ORCID

Funder

Fritz Thyssen Stiftung

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference48 articles.

1. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism;JA Engelman;Nat Rev Genet,2006

2. PI3K/Akt: getting it right matters;TF Franke;Oncogene,2008

3. mTOR signaling at a glance;M Laplante;J Cell Sci,2009

4. AKT/PKB signaling: navigating downstream;BD Manning;Cell,2007

5. mTOR, translation initiation and cancer;Y Mamane;Oncogene,2006

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging molecular therapies in the treatment of bladder cancer;Exploration of Targeted Anti-tumor Therapy;2024-08-29

2. Assessments of prostate cancer cell functions highlight differences between a pan‐PI3K/mTOR inhibitor, gedatolisib, and single‐node inhibitors of the PI3K/AKT/mTOR pathway;Molecular Oncology;2024-08-02

3. Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models;npj Breast Cancer;2024-06-05

4. Targeting PI3K/AKT/mTOR signaling to overcome drug resistance in cancer;Chemico-Biological Interactions;2024-06

5. Targeting a lineage-specific PI3Kɣ–Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule;Nature Cancer;2024-05-30